STOCK TITAN

Pyxis Oncology to Host Live Webcast on Updated MICVO Phase 1 Monotherapy Data Demonstrating Durable Response in 2L+ R/M HNSCC Following Late-Breaking Oral Presentation at EORTC-NCI-AACR Symposium

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Pyxis Oncology (PYXS) reported updated Phase 1 results for MICVO alone in second-line or later treatment of recurrent or metastatic head and neck squamous cell carcinoma.

As of October 14, 2026, among 33 patients evaluable for efficacy who received doses at or below the cap, the confirmed response rate was 39% and disease control was 94%. Median response duration was 9.2 months, median time without disease progression was 6.7 months and the estimated probability of survival at 12 months was 81%. Median time without progression on the same patients’ most recent prior therapy was 4.2 months.

All six patients with grade 3 peripheral neuropathy (nerve damage) improved, five to grade 1 or better. Pyxis plans to start the global Phase 3 Headliner trial in mid-2027 and expects more mature overall survival data in the first half of 2027.

Loading...
Loading translation...
16 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 3 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate pointConfirmed response rate was 39% among 33 evaluable patients treated at or below the dose cap
  • Moderate pointMedian response duration was 9.2 months
  • Moderate pointMedian time without progression was 6.7 months on MICVO versus 4.2 months on the same patients’ most recent prior therapy
  • Moderate pointEstimated 12-month survival probability was 81%
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Phase 3 Headliner trial is planned to start globally in mid-2027
11 minor points
  • Minor pointDisease control rate was 94%
  • Minor pointConfirmed plus unconfirmed response rate was 52%
  • Minor pointGrade 3 nerve damage improved in all six affected patients: five to grade 1 or better and one to grade 2; no new cases were reported
  • Minor pointConfirmed response rate by dose group was 60% in five patients at the cap versus 44% in nine above it
  • Minor pointDiscontinuation due to treatment-related side effects was 20% at the cap versus 56% above it
  • Minor pointGrade 3 treatment-related nerve damage occurred in 0% of patients at the cap versus 67% above it
  • Minor pointConfirmed response by human papillomavirus status was 41% in HPV-positive disease and 38% in HPV-unrelated disease
  • Minor pointConfirmed response by prior EGFR inhibitor use was 33% with prior use, 60% in the five-patient novel-inhibitor subgroup and 47% without prior use
  • Minor pointConfirmed response by treatment line was 46% in second line and 40% in third line
  • Minor pointConfirmed response by prior taxane use was 39% with prior use and 40% without it
  • Minor point. Forward-looking: it has not happened yet and may not happen.More mature overall survival data are expected in the first half of 2027

Negative

  • Minor pointPeripheral neuropathy of any grade occurred in 68% of patients with prior taxane use versus 36% without it
  • Minor pointGrade 3 peripheral neuropathy occurred in 20% of patients with prior taxane use versus 9% without it
  • Minor pointFour partial responses remained unconfirmed: three patients later had disease progression and one was lost to follow-up

News Explained

Pyxis describes the overall tolerability profile as manageable, while its dose-group table reports Grade 3 treatment-related peripheral neuropathy in 67% of patients dosed above the cap (N=9), versus 0% of capped-dose patients (N=5); treatment-related discontinuation was 56% versus 20%, respectively.

Key Figures

Confirmed objective response rate: 39% Disease control rate: 94% Median progression-free survival: 6.7 months +5 more
Confirmed objective response rate
39%
MICVO Phase 1 monotherapy; data as of October 14, 2026
Disease control rate
94%
MICVO Phase 1 monotherapy; 33 efficacy-evaluable patients
Median progression-free survival
6.7 months
MICVO Phase 1 monotherapy; data as of October 14, 2026
12-month overall survival probability
81%
MICVO Phase 1 monotherapy; data as of October 14, 2026
Median duration of response
9.2 months
MICVO Phase 1 monotherapy; data as of October 14, 2026
Efficacy-evaluable patients
33 patients
MICVO Phase 1 monotherapy
Median PFS increase versus most recent prior therapy
50%
Company-reported comparison in the MICVO Phase 1 study
Grade 3 peripheral neuropathy resolving to Grade 1 or better
83%
6 patients with Grade 3 peripheral neuropathy

Previous Clinical trial Reports

1 past event · Latest: Sep 09
Same Type 1 event
  1. Sep 09

    Phase 1 data

    24h Move
    -13.1%

    Earlier Phase 1 update reported a 36% confirmed response rate and 6.2-month median progression-free survival.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

objective response rate, progression-free survival, disease control rate, antibody-drug conjugate, +1 more
5 terms
objective response rate medical
"39% confirmed objective response rate (cORR)"
The objective response rate (ORR) is the percentage of patients in a clinical trial whose tumors measurably shrink or disappear according to preset rules. Investors use it as a quick, objective signal of a drug’s ability to produce a clear treatment effect—like counting how many plants visibly respond after applying a new fertilizer—and higher ORR can improve odds of regulatory approval, commercial success, and company valuation.
progression-free survival medical
"median progression-free survival (mPFS) of 6.7 months"
Progression-free survival is the length of time during and after a treatment that a patient's disease does not get worse, measured from the start of treatment until the disease shows measurable signs of progression or the patient dies. Investors care because longer progression-free survival in clinical trials often signals that a drug is effective, improving chances of regulatory approval, market adoption, and revenue potential—think of it as a stopwatch showing how long a therapy can keep the illness at bay.
disease control rate medical
"94% disease control rate (DCR)"
The disease control rate is the share of patients in a clinical trial whose cancer or condition either shrinks or stops getting worse for a specified period after treatment. Think of it like the percentage of people for whom a treatment hits pause or nudges back the problem rather than letting it progress; higher rates suggest the therapy can meaningfully limit disease, which matters to investors assessing a drug’s potential efficacy and commercial value.
antibody-drug conjugate medical
"an investigational antibody-drug conjugate (ADC)"
An antibody-drug conjugate is a targeted medicine that combines an antibody, which can identify specific cells, with a powerful drug designed to destroy those cells. This approach allows for precise treatment, minimizing damage to healthy tissue. For investors, developments in this area can signal advances in cancer therapies and potential growth opportunities in the biotech sector.
fast track designation regulatory
"MICVO received Fast Track Designation from the U.S. Food and Drug Administration"
Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Updated data from a more mature October 2026 data cutoff show rapid and deep responses, with a 39% confirmed ORR, median duration of response of 9.2 months and median PFS of 6.7 months

Clinical activity consistent across HPV status and prior-treatment subgroups, with a manageable safety profile

Results support advancement of MICVO into the global Phase 3 HeadlinerSM trial in 2L+ R/M HNSCC, planned to initiate in mid-2027

Company to host a live webcast on November 19, 2026, at 7:00 a.m. EST, following the late-breaking oral presentation

BOSTON, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced updated results from its ongoing global Phase 1 monotherapy study evaluating micvotabart pelidotin (MICVO) in patients with second-line and beyond recurrent/metastatic head and neck squamous cell carcinoma (2L+ R/M HNSCC).

The results will be presented on November 19, 2026, by Faye Johnson, M.D., Ph.D., professor of thoracic/head and neck medical oncology at The University of Texas MD Anderson Cancer Center, in a late-breaking oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.

The updated data, as of October 14, 2026, demonstrated a 39% confirmed objective response rate (cORR), 94% disease control rate (DCR), median progression-free survival (mPFS) of 6.7 months, 12-month overall survival (OS) probability of 81%, and newly reported median duration of response (mDOR) of 9.2 months among 33 efficacy evaluable patients dosed at 5.4 mg/kg intravenously once every three weeks with a dose equivalent to or below a dose cap. Together, these results provide further evidence of clinical activity across HPV statuses and prior-treatment subgroups, with an expected and manageable tolerability profile.

“We are grateful to the EORTC-NCI-AACR Symposium for highlighting these updated MICVO data in 2L+ R/M HNSCC, and to Dr. Johnson for presenting these important new results,” said Tom Civik, Chief Executive Officer and Chairman of Pyxis Oncology. “The data from October show improvements across multiple key clinical activity endpoints with a novel analysis showing that MICVO increased mPFS by 50% versus the most recent prior therapy patients had received before MICVO. We are also very happy to report that our clinical strategy for managing safety has had the intended impact. There have been no new cases of Grade 3 peripheral neuropathy and the six patients that experienced Grade 3 peripheral neuropathy have all improved with five of the six patients resolving to Grade 1 or better. Collectively, this updated data profile, and the new analyses further support our plan to advance MICVO into the global Phase 3 HeadlinerSM trial in 2L+ R/M HNSCC, which we expect to initiate in mid-2027. With important regulatory meetings in the near term and more mature overall survival (OS) data expected in the first half of 2027, we remain confident in our path forward.”

“For patients whose disease progresses after platinum chemotherapy and immunotherapy, there remains a substantial unmet medical need, particularly as we anticipate broader use of EGFR-targeted therapies in earlier lines of treatment,” said Dr. Johnson. “It is reassuring to see responses that last in this setting and, if confirmed in a larger study, MICVO could potentially offer these patients a meaningful new treatment option.”

Updated MICVO Phase 1 Monotherapy Trial Results as of October 14, 2026

Table 1: Survival and Durability

CategoriesOctober 2026
Median progression-free survival (mPFS), months6.7
12-month overall survival (OS) probability, %81%
Median duration of response (mDOR), months9.2

Data as of 14-Oct-2026

Table 2: Responses

CategoriesGroups (N)October 2026
OverallcORR (N=33)39%
c+uORR (N=33)52%
DCR (N=33)94%
HPV StatuscORR HPV+ (N=17)41%
cORR HPV-Unrelated (N=16)38%
Prior EGFRicORR Prior EGFRi (N=18)33%
cORR Prior Novel EGFRi (N=5)60%
cORR No EGFRi (N=15)47%
Line of TherapycORR 2L (N=11)46%
cORR 3L (N=20)40%
Prior TaxanecORR Prior Taxane (N=23)39%
cORR No Taxane (N=10)40%

Data as of 14-Oct-2026; c+uORR: 4 patients with uPR include: N=2 patients had PD on subsequent scan, N=1 lost to follow-up, and N=1 had 3 subsequent tumor assessments as not evaluable and the following scan as PD due to growth of a non-target lesion 216 days after first dose.
Abbreviations: 2L: second-line; 3L: third-line; cORR: confirmed objective response rate; c+uORR: confirmed plus unconfirmed objective response rate; DCR: disease control rate; HPV: human papillomavirus; EGFRi: EGFR inhibitor; n/N: number of patients; uPR: unconfirmed partial response

Table 3: Incremental Analysis from August 18, 2026 Data

CategoriesGroups (N)October 2026
Resolution of Grade 3 Peripheral NeuropathyGrade 3 Peripheral Neuropathy (N=6) Resolving to Grade 1 or better83%
Grade 3 Peripheral Neuropathy (N=6) Resolving to Grade 217%
Grade 3 Peripheral Neuropathy (N=6) Not Resolving0%
Peripheral Neuropathy and prior taxane useAny Grade Peripheral Neuropathy for patients with (N=25) or without (N=11) prior taxanePrior Taxane: 68%
No Prior Taxane: 36%
Grade 3 Peripheral Neuropathy for patients with (N=25) or without (N=11) prior taxanePrior Taxane: 20%
No Prior Taxane: 9%
Impact of dose cap for males above 80kg and females above 70kgcORR dosed above cap (N=9) vs. patients receiving capped dose (N=5)Dosed above cap: 44%
Capped dose: 60%
TRAEs leading to discontinuation dosed above cap (N=9) vs. patients receiving capped dose (N=5)Dosed above cap d/c: 56%
Capped dose d/c: 20%
Grade 3 Treatment-Related Peripheral Neuropathy dosed above cap (N=9) vs. patients receiving capped dose (N=5)Dosed above cap Gr3 PN: 67%
Capped dose Gr3 PN: 0%
PFS on MICVO vs. Prior TherapymPFS on most recent prior therapy (N=33), months (95% CI)4.2 (2.8-5.6)
mPFS on MICVO (N=33), months (95% CI)6.7 (4.8-9.0)

Data as of 14-Oct-2026
Abbreviations: cORR: confirmed objective response rate; d/c: discontinue; TRAE: treatment-related adverse event; Gr: grade; MICVO: micvotabart pelidotin; mPFS: median progression-free survival; N: number of patients; PN: Peripheral Neuropathy; CI: confidence interval.

Late-Breaking Oral Presentation Details
Title: Phase 1 study of micvotabart pelidotin (MICVO) monotherapy in previously treated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
Presenter: Faye Johnson, M.D., Ph.D., The University of Texas MD Anderson Cancer Center
Session: Proffered Papers: Clinical Trials
Abstract number: 3LBA
Date and time: Thursday, November 19, 2026, 10:00 - 11:30 CET
Location: Room 111 + 112

Live Webcast
Pyxis Oncology will host a live webcast on Thursday, November 19, 2026, at 7:00 a.m. Eastern Standard Time / 1:00 p.m. Central European Time to discuss the updated MICVO results following the late-breaking oral presentation at the EORTC-NCI-AACR Symposium. To participate in the live webcast, participants may register in advance here. The event and accompanying slides can be accessed by visiting the investor relations section of the Company's website at https://ir.pyxisoncology.com. An archived webcast will be available on the Company's website following the event.

About Micvotabart Pelidotin (MICVO)
Micvotabart pelidotin (MICVO, formerly PYX-201) is an investigational antibody-drug conjugate (ADC) that uniquely targets extradomain-B of fibronectin (EDB+FN), a non-cellular structural component of the tumor extracellular matrix. MICVO is designed to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing extracellular matrix density, inhibiting tumor angiogenesis and mobilizing an anti-tumor immune response.

MICVO received Fast Track Designation from the U.S. Food and Drug Administration for the treatment of adult patients with R/M HNSCC whose disease has progressed following treatment with platinum-based chemotherapy and an anti-PD-(L)1 therapy.

About Pyxis Oncology
Pyxis Oncology, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for difficult-to-treat cancers. The Company’s lead candidate, micvotabart pelidotin (MICVO), is a first-in-concept antibody-drug conjugate (ADC) that targets extradomain-B of fibronectin (EDB+FN), a non-cellular structural component of the tumor extracellular matrix (ECM). EDB+FN is selectively overexpressed in the tumor microenvironment of a wide range of solid tumors and largely absent from normal adult tissues. MICVO is designed to treat solid tumors through a three-pronged mechanism of action: direct cancer cell killing, bystander effect and immunogenic cell death. MICVO is currently being evaluated as monotherapy in a Phase 1 clinical study in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) and in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in a Phase 1/2 clinical study in patients with R/M HNSCC and other solid tumors. Pyxis Oncology is focused on advancing MICVO, with the goal of improving outcomes for patients living with R/M HNSCC and contributing to meaningful progress in cancer treatment.

To learn more, visit www.pyxisoncology.com or follow us on LinkedIn.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Forward-Looking Statements
This press release contains forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this press release, including without limitation statements regarding the Company’s plans to develop, manufacture and commercialize its product candidate, including micvotabart pelidotin (‘MICVO’); preliminary data, timing and progress of the Company’s ongoing clinical trials; the expected results of the Company’s clinical trials; the Company’s planned global Phase 3 trial of MICVO, including the expected timing of its initiation; the timing and outcome of anticipated regulatory interactions; the expected timing of additional data, including more mature overall survival data; the ability of preliminary, initial and topline clinical data to reduce the potential risks associated with the development of MICVO and be confirmed with clinical trial progression, including the safety, tolerability, and potential efficacy of MICVO; the potential differentiation, advantage or effectiveness of MICVO compared to other approved products or products in development; the dosage and treatment potential of MICVO; the size and future of the market; the plans and objectives of management, and the future results of operations and financial position of the Company, are forward-looking statements. These statements are neither promises nor guarantees, but are statements that involve known and unknown risks, uncertainties and other important factors that are in some cases beyond the Company’s control that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the risks inherent in drug research and development, the Company’s projected cash runway and potential needs for additional funding; the lengthy, expensive, and uncertain process of clinical drug development, including potential delays in or failure to obtain regulatory approvals; the Company’s reliance on third parties and collaborators to conduct clinical trials, manufacture its product candidate, and develop and commercialize its product candidate; and the Company’s ability to compete successfully against other drug candidates. Accordingly, investors should not rely upon forward-looking statements as predictions of future events. Except as required by applicable law, the Company undertakes no obligation to update publicly or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Additionally, investors should read risk factors in the section titled “Risk Factors” set forth in Part II, Item 1A. of the Company’s Quarterly Report on Form 10-Q filed on November 5, 2026, and the Company’s other filings, each of which is on file with the Securities and Exchange Commission.

Pyxis Oncology Contact
IR@pyxisoncology.com



FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Pyxis Oncology’s updated MICVO Phase 1 results show in head and neck cancer?

MICVO had a 39% confirmed response rate among 33 evaluable patients treated at or below the dose cap. As of October 14, 2026, median response duration was 9.2 months, median time without disease progression was 6.7 months, and the estimated probability of survival at 12 months was 81%.

When does Pyxis Oncology plan to start the MICVO Phase 3 Headliner trial?

Pyxis Oncology plans to start the global Phase 3 Headliner trial in mid-2027. It will study MICVO in second-line or later treatment of recurrent or metastatic head and neck squamous cell carcinoma.

How did side effects compare at and above the MICVO dose cap in Pyxis Oncology’s Phase 1 study?

Treatment-related side effects led to discontinuation in 20% of patients at the cap versus 56% above it. Grade 3 treatment-related peripheral neuropathy occurred in 0% versus 67%, respectively. The comparison involved five patients at the cap and nine above it.

What happened to the unconfirmed responses in Pyxis Oncology’s MICVO Phase 1 trial?

Of the four patients with unconfirmed partial responses, three later had disease progression and one was lost to follow-up. Two had progression on a subsequent scan. The third had three tumor assessments that could not be evaluated before a scan showed progression due to growth of a lesion not designated for measurement, 216 days after the first dose.

Keep reading